Fostamatinib resistance management

Fostamatinib (Fostamatinib) is a drug used to treat chronic immune thrombocytopenia (ITP). However, in clinical application, some patients may develop drug resistance, which will have a certain impact on the treatment effect. In the face of drug resistance, treatment strategies need to comprehensively consider the individual differences and specific conditions of patients.

Assessment of drug resistance requires careful monitoring of platelet counts and other relevant indicators during treatment. If a patient's platelet levels fail to achieve the desired effect or fluctuate significantly after a reasonable period of treatment, doctors should consider drug resistance. In this case, doctors usually first conduct a comprehensive evaluation, including ruling out other potential factors, such as drug interactions, comorbidities, or noncompliance, to determine the true nature of resistance.

One way to deal with drug resistance is to adjust the treatment plan. Physicians may consider increasing the dose of fotantinib, especially if the patient does not respond well to the initial dose. At the same time, the combined use of other therapeutic drugs, such as glucocorticoids or other immunomodulators, can also be considered to enhance the therapeutic effect. This combination therapy helps overcome drug resistance and improve platelet counts.

In addition, if patients continue to be refractory to fotantinib, they may need to switch to other types of treatment. For example, patients could switch to other novel medications or consider splenectomy surgery, which may lead to significant improvement in some severe cases. The spleen plays an important role in the immune response, and removing the spleen may help reduce damage to platelets, thereby increasing platelet counts.

Reference materials:https://karger.com/aha/article/147/3/333/864227/Fostamatinib-or-Thrombopoietin-for-the-Treatment